The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
McDonald's China Faces Backlash for Food Hygiene Violations 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Skepta and PUMA Launch Groundbreaking Collection 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
